DBV Technologies (NASDAQ:DBVT) PT Raised to $7.00

DBV Technologies (NASDAQ:DBVT - Get Free Report) had its target price upped by equities research analysts at HC Wainwright from $5.00 to $7.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a "buy" rating on the stock.

Other equities analysts have also issued research reports about the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Tuesday, September 24th. StockNews.com started coverage on DBV Technologies in a report on Monday. They issued a "hold" rating for the company.

DBV Technologies Trading Up 23.5 %

Shares of NASDAQ DBVT traded up $0.16 during mid-day trading on Thursday, reaching $0.84. The company had a trading volume of 7,056,346 shares, compared to its average volume of 230,904. The company has a 50-day moving average price of $0.78 and a two-hundred day moving average price of $0.96. The stock has a market cap of $81.05 million, a PE ratio of -1.00 and a beta of 0.67. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.28.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The company had revenue of $1.16 million during the quarter, compared to analysts' expectations of $1.42 million. During the same period in the prior year, the business posted ($0.26) EPS. On average, research analysts expect that DBV Technologies will post -1.43 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 6.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,568,909 shares of the company's stock after acquiring an additional 327,345 shares during the period. DBV Technologies comprises approximately 0.2% of Yiheng Capital Management L.P.'s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.